Gene · 4610
Papers2,575
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
261 to 280 of 2,575
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Non-coding RNAs in breast cancer: with a focus on glucose metabolism reprogramming. | Discov Oncol | 2023 | 37204526 | PubTator, text mining | PubMed |
| The Crosstalk and Clinical Implications of CircRNAs and Glucose Metabolism in Gastrointestinal Cancers. | Cancers (Basel) | 2023 | 37190158 | PubTator, text mining | PubMed |
| Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study. | BMC Cancer | 2023 | 37189075 | PubTator, text mining | PubMed |
| MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma. | Int J Mol Sci | 2023 | 37175848 | PubTator, text mining | PubMed |
| High Intrinsic Oncogenic Potential in the Myc-Box-Deficient Hydra Myc3 Protein. | Cells | 2023 | 37174665 | PubTator, text mining | PubMed |
| 4-[(5-Methyl-1H-pyrazol-3-yl)amino]-2H-phenyl-1-phthalazinone Inhibits MCPyV T Antigen Expression in Merkel Cell Carcinoma Independent of Aurora Kinase A. | Cancers (Basel) | 2023 | 37174007 | PubTator, text mining | PubMed |
| Proof-of-Concept for Liquid Biopsy Disease Monitoring of MYC-Amplified Group 3 Medulloblastoma by Droplet Digital PCR. | Cancers (Basel) | 2023 | 37173990 | PubTator, text mining | PubMed |
| RNA N6-methyladenosine reader IGF2BP3 interacts with MYCN and facilitates neuroblastoma cell proliferation. | Cell Death Discov | 2023 | 37156775 | PubTator, text mining | PubMed |
| Primary small cell thyroid carcinoma combined with poorly differentiated thyroid carcinoma, evidence for a common origin: A case report. | Oncol Lett | 2023 | 37153036 | PubTator, text mining | PubMed |
| Neurocan expression associates with better survival and viral positivity in Merkel cell carcinoma. | PLoS One | 2023 | 37146093 | PubTator, text mining | PubMed |
| Corrigendum: The MYC paralog-PARP1 axis as a potential therapeutic target in MYC paralog-activated small cell lung cancer. | Front Oncol | 2023 | 37124537 | PubTator, text mining | PubMed |
| Targeting Myc-driven stress addiction in colorectal cancer. | Drug Resist Updat | 2023 | 37119690 | PubTator, text mining | PubMed |
| DNA-PKcs as an upstream mediator of OCT4-induced MYC activation in small cell lung cancer. | Biochim Biophys Acta Gene Regul Mech | 2023 | 37116859 | PubTator, text mining | PubMed |
| Alterations and Co-Occurrence of C-MYC, N-MYC, and L-MYC Expression are Related to Clinical Outcomes in Various Cancers. | Int J Stem Cells | 2023 | 37105559 | PubTator, text mining | PubMed |
| In vitro erythrocyte production using human-induced pluripotent stem cells: determining the best hematopoietic stem cell sources. | Stem Cell Res Ther | 2023 | 37101221 | PubTator, text mining | PubMed |
| MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat. | J Exp Clin Cancer Res | 2023 | 37098540 | PubTator, text mining | PubMed |
| HiPSC-derived cardiomyocyte to model Brugada syndrome: both asymptomatic and symptomatic mutation carriers reveal increased arrhythmogenicity. | BMC Cardiovasc Disord | 2023 | 37098502 | PubTator, text mining | PubMed |
| Multi-omics analysis of the Indian ovarian cancer cohort revealed histotype-specific mutation and gene expression patterns. | Front Genet | 2023 | 37091785 | PubTator, text mining | PubMed |
| Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation. | Cancer Discov | 2023 | 37062002 | PubTator, text mining | PubMed |
| Application of Human Stem Cells to Model Genetic Sensorineural Hearing Loss and Meniere Disease. | Cells | 2023 | 37048061 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4610/papers?page=14